APGE
Apogee Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$135.07
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 408.0K | 1.4M | — | — | — |
| Gross Profit | (408.0K) | (1.4M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 240.7M | 214.7M | 167.9M | 68.4M | 27.8M |
| SG&A Expense | 83.1M | 70.9M | 49.0M | 24.6M | 2.9M |
| General & Admin Expense | 83.5M | 70.9M | 49.0M | 24.6M | 2.9M |
| Selling & Marketing Expense | (408.0K) | — | — | — | — |
| Other Expenses | 3.9M | — | — | — | — |
| Total Operating Expenses | 327.7M | 284.2M | 216.9M | 93.0M | 30.7M |
| Cost and Expenses | 328.1M | 285.6M | 216.9M | 93.0M | 30.7M |
| Operating Income (EBIT) | (328.1M) | (285.6M) | (216.9M) | (93.0M) | (30.7M) |
| Non-Operating | |||||
| Interest Income | 5.6M | 30.0M | 34.7M | 9.0M | 92.0K |
| Interest Expense | 1.6M | — | — | — | 9.2M |
| Net Interest Income | 4.0M | 30.0M | 34.7M | 9.0M | (9.1M) |
| Other Non-Op Income/Expense | 34.0M | 30.0M | 34.7M | 9.0M | (9.1M) |
| Non-Operating Income (excl Interest) | (35.6M) | (30.0M) | (34.7M) | (9.0M) | 9.1M |
| EBT (Pre-Tax Income) | (294.1M) | (255.6M) | (182.1M) | (84.0M) | (39.8M) |
| Income Tax Expense | 280.0K | 278.0K | 18.0K | — | — |
| Bottom Line | |||||
| Net Income | (294.4M) | (255.8M) | (182.1M) | (84.0M) | (39.8M) |
| Earnings from Cont. Ops | (294.4M) | (255.8M) | (182.1M) | (84.0M) | (39.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (294.4M) | (255.8M) | (182.1M) | (84.0M) | (39.8M) |
| Per Share | |||||
| Basic EPS | ($4.34) | ($4.22) | ($3.30) | ($1.66) | ($0.79) |
| Diluted EPS | ($4.34) | ($4.22) | ($3.30) | ($1.66) | ($0.79) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 75.4M | 60.7M | 55.2M | 50.7M | 50.7M |
| Diluted Shares Outstanding | 75.4M | 60.7M | 55.2M | 50.7M | 50.7M |
| Profitability Metrics | |||||
| EBITDA | (291.3M) | (254.1M) | (181.9M) | (75.0M) | (39.8M) |
| D&A | 1.2M | 1.4M | 189.0K | 9.0M | — |
| EBIT | (292.5M) | (255.6M) | (182.1M) | (84.0M) | (39.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026